Psychedelic-assisted therapy: An innovative approach to treating treatment-resistant depression

Introduction

In recent years, psychedelic-assisted therapy has established itself as a promising treatment method for treatment-resistant depression (TRD). At the Las Almas Institutes in Vienna and Mallorca, psychedelic-assisted therapy is used within an integrative treatment approach. The combination of infusion treatments and neuroscientifically based therapeutic procedures can enable clinically relevant improvements, particularly in cases where other treatments have not been sufficiently effective.

Note: Treatment is administered exclusively under medical supervision and following a thorough medical examination. The active ingredients used are subject to applicable national and European drug regulations. Patients are fully informed about the benefits, risks, and their specific application status before the start of treatment.

Pharmacological mechanism of action

The substances used in psychedelic-assisted therapy act via specific receptor systems in the brain and can influence processes of synaptic plasticity. Studies indicate that such substances can enhance glutamatergic neurotransmission and contribute to increased synaptic plasticity (Zarate et al., 2006).

Furthermore, research literature discusses the possibility that these substances can influence the expression of brain-derived neurotrophic factor (BDNF) and support neuroprotective processes (Autry & Monteggia, 2012). These mechanisms of action differ from those of classic antidepressants, which target monoaminergic systems.

Psychedelic-assisted therapy for treatment-resistant depression

Treatment-resistant depression (TRD) refers to depressive disorders in which at least two appropriately conducted treatment attempts with different antidepressants have not shown sufficient efficacy. It presents a particular medical challenge. It is estimated that approximately 30% of patients with major depression do not respond adequately to standard drug treatments (Rush et al., 2006).

Scientific studies suggest that infusion treatments used in psychedelic-assisted therapy can lead to a rapid reduction in depressive symptoms in certain patients with TRD (Diazgranados et al., 2010). However, individual efficacy and tolerability are unpredictable and can vary considerably from person to person.

Important note: Some of the substances used in psychedelic-assisted therapy are not approved as medicinal products for the treatment of depression in Spain and the EU. Their use is permitted on an off-label basis, requiring comprehensive patient education, a careful benefit-risk assessment by the treating physician, and the patient's explicit written consent.

Accompanying therapeutic procedures

Psychedelic-assisted therapy at the Las Almas Institutes is always embedded in a comprehensive, interdisciplinary treatment concept:

  • Repetitive transcranial magnetic stimulation (rTMS): A non-invasive procedure for stimulating cortical areas, which is being scientifically investigated in the treatment of depression.
  • Neurofeedback: Methods to support the self-regulation of neuronal activity.
  • Hypnotherapy: Psychotherapeutic method for dealing with emotional stress.
  • Sports and exercise therapy: Physical activity to support neurophysiological health.
  • Mindfulness-based methods: Evidence-based methods for stress reduction and promoting emotion regulation.

Scientific evidence

The existing research literature on psychedelic-assisted therapy for TRD includes, among others, the following works:

  • Zarate et al. (2006): Investigation of rapid antidepressant effects in treatment-resistant depression.
  • Diazgranados et al. (2010): Clinical observations on symptom reduction after infusion treatments.

The Las Almas Institute Mallorca works in close cooperation with international research institutions to continuously develop and scientifically support the treatment protocols.

The studies mentioned are for scientific information purposes only. Their results are not applicable to every individual treatment case.

Conclusion

Psychedelic-assisted therapy, as part of a comprehensive, medically supervised treatment plan, offers a potential approach for patients with treatment-resistant depression for whom conventional treatments have not been sufficiently effective. The Las Almas Institute places the highest value on medical care, patient safety, and compliance with all applicable health regulations.

Further information and scientific publications on the methods used can be found on our "Studies" page: https://www.lasalmasgroup.com/studien/

For a free consultation, contact the Las Almas Institute in Vienna or Mallorca.